Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results From a Post hoc Analysis

Dover, Jeffrey S.; Shridharani, Sachin M.; Bloom, Jason D.; Somogyi, Christine; Gallagher, Conor J.

doi:10.1097/dss.0000000000001484

Cited by 11 publications

(17 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Figure 5 summarizes the relationship of the MOA of ATX-101, the development of injection-site inflammation, and clinical efficacy. 5,21,22,26,28,[30][31][32] As described earlier, injection of ATX-101 results in adipocytolysis, with destroyed adipocytes no longer able to store or accumulate fat. 16,17,31 Adipocytolysis and the release of cell contents and membrane fragments elicit a mild, local inflammatory response, resulting in neutrophilic inflammation and attracting macrophages.…”

Section: The Links Between Mechanism Of Action Injection-site Inflamm...mentioning

confidence: 82%

“…21 At this point, many patients will experience an improvement in submental appearance, although caliper-measured submental fat thickness may be increased due to residual induration. 22 Caliper measurements, however, are a crude objective assessment of fat thickness used in clinical trials and are limited in their utility for confirming reduction of submental fat volume in clinical practice. 25,33 Gradual improvement in submental fat may continue beyond It has been hypothesized that, following submental ATX-101-induced adipocytolysis and subsequent inflammation, tissue remodeling and neocollagenesis may occur over several months.…”

Section: The Links Between Mechanism Of Action Injection-site Inflamm...mentioning

confidence: 99%

See 1 more Smart Citation

Submental Area Treatment with ATX-101: Relationship of Mechanism of Action, Tissue Response, and Efficacy

Humphrey¹,

Yoelin

Friedmann

et al. 2022

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background: ATX-101 is an injectable, synthetically derived formulation of deoxycholic acid used for submental fat reduction. Methods: A narrative review of references relevant to the mechanism of action of ATX-101 and its relationship to efficacy and inflammatory adverse events was conducted. Results: When injected into subcutaneous fat, deoxycholic acid physically disrupts adipocyte cell membranes, leading to local adipocytolysis, cell death, and a mild, local inflammatory reaction consisting of macrophage infiltration and fibroblast recruitment. At Day 28 postinjection, inflammation largely resolves, and key histologic features include fibrotic septal thickening, neovascularization, and atrophy of fat lobules. Based on the mechanism of action of ATX-101 and the demonstrated inflammatory response, localized inflammation and swelling are expected following treatment. Indeed, postinjection swelling and other local injection-site events, including pain, erythema, and bruising, are common during and after treatment. Because of inflammatory sequelae following injection, reduction in submental fat is gradual and may require months before the full response is apparent. Patients may also require multiple treatment sessions to achieve their treatment goals. Repeated treatments may result in less pain and swelling over time owing to a combination of factors, including less target tissue allowing for lower doses/injection volumes, persistent numbness, and greater tissue integrity from thickened fibrous septa. Conclusions: Physicians can manage expectations by counseling patients that, based on the mechanism of action of ATX-101 and data from pivotal clinical trials, ATX-101 treatment results in localized inflammation/swelling and gradual submental fat reduction. Patient education about common local adverse events is critical.

show abstract

Section: The Links Between Mechanism Of Action Injection-site Inflamm...mentioning

confidence: 82%

Section: The Links Between Mechanism Of Action Injection-site Inflamm...mentioning

confidence: 99%

Submental Area Treatment with ATX-101: Relationship of Mechanism of Action, Tissue Response, and Efficacy

Humphrey¹,

Yoelin

Friedmann

et al. 2022

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

show abstract

“…ATX-101 treatments should be spaced a minimum of 4 weeks apart. 22 In our collective experience, treatment intervals range from 6–8 weeks. In CONTOUR, the ATX-101 treatment interval ranged from 9–17 weeks 15 to allow sufficient time for resolution of the inflammatory response and remodeling of the treatment area.…”

Section: Guidance For Administration Of Atx-101mentioning

confidence: 98%

“…Unlike these treatments, the full treatment effects of ATX-101 take a few months, as the SMF is gradually reduced and tissue remodeling takes place. 22 Individuals may have varied response with respect to level of response and how many treatments are needed before achieving response. 14 ATX-101 treatment will be individually tailored based on the patient’s SMF severity, as well as treatment goals and response.…”

Section: Managing Patient Expectations Of Atx-101 Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Best Clinical Practices with ATX-101 for Submental Fat Reduction: Patient-related Factors and Physician Considerations

Teller

Chiu²,

Chesnut

et al. 2021

Plastic and Reconstructive Surgery - Global Open

Self Cite

View full text Add to dashboard Cite

Background: Submental fat can be reduced with ATX-101 (deoxycholic acid injection), a customizable and minimally invasive alternative to liposuction. In the years since its approval, the treatment patterns of ATX-101 have evolved. Methods: A panel of experienced physicians from the United States gathered to generate best practices for the use of ATX-101 in submental contouring. Results: The expert panel provided their insights on appropriate patient selection, managing patient expectations of ATX-101 treatment outcomes, and adverse events, and guidance on ATX-101 administration for optimal outcomes are presented here. Conclusion: These best clinical practices on the use of ATX-101 for the reduction of submental fat should enable physicians to enhance the patient treatment experience and outcomes.

show abstract

Is deoxycholic acid able to reduce submental fat and increase patient satisfaction when compared to placebo groups? A systematic review

Vertuan¹,

Honório²,

Queiroz³

et al. 2022

Journal of Plastic, Reconstructive & Aesthetic Surgery

View full text Add to dashboard Cite

Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results From a Post hoc Analysis

Cited by 11 publications

References 4 publications

Submental Area Treatment with ATX-101: Relationship of Mechanism of Action, Tissue Response, and Efficacy

Submental Area Treatment with ATX-101: Relationship of Mechanism of Action, Tissue Response, and Efficacy

Best Clinical Practices with ATX-101 for Submental Fat Reduction: Patient-related Factors and Physician Considerations

Is deoxycholic acid able to reduce submental fat and increase patient satisfaction when compared to placebo groups? A systematic review

Contact Info

Product

Resources

About